Core Points - The board of directors of Renfu Pharmaceutical Group Co., Ltd. held its second meeting on August 26, 2025, to discuss various proposals and resolutions [1][2][3] Meeting Details - The meeting was attended by all nine directors, with four participating in person and the rest voting via communication [1] - The meeting was deemed legally valid and compliant with relevant regulations and the company's articles of association [1] Resolutions Passed - The board approved the full and summary reports for the company's 2025 semi-annual report, which had previously been reviewed by the audit committee [2] - The board agreed to reappoint Da Xin Certified Public Accountants as the auditing firm for the 2025 financial year, with the 2024 audit fees totaling 5.2 million yuan, including 1.5 million yuan for internal control audits [2][3] - A financial services agreement with China Merchants Group Finance Co., Ltd. was approved, pending shareholder approval [3][4] - The board also approved a risk assessment report regarding China Merchants Group Finance Co., Ltd. [4] - A risk disposal plan for financial business with China Merchants Group Finance Co., Ltd. was also approved [5] Upcoming Events - The board scheduled the fourth extraordinary general meeting for September 12, 2025, to review the reappointment of the auditing firm and the financial services agreement [5][6]

Group 1 - The ninth supervisory board meeting of the company was held on August 11, 2025, via telephone and email notifications to all supervisors [1] - The supervisory board reviewed and approved the company's 2025 semi-annual report, confirming that the report complies with legal and regulatory requirements and accurately reflects the company's actual situation [1] - The voting results for the approval of the semi-annual report were unanimous, with 5 votes in favor and no votes against or abstentions [1] Group 2 - The supervisory board also reviewed the risk assessment report of Sinochem Group Financial Co., Ltd., which adequately reflects the financial company's operational qualifications, business, and risk status [1] - The chairman of the supervisory board recused himself from voting on the risk assessment report due to his position at the related party, Sinochem Holdings Corporation [1] - The voting results for the risk assessment report were 4 votes in favor, with no votes against or abstentions [2]

Core Viewpoint - The board of directors of Beijing Tiantan Biological Products Co., Ltd. has approved several key resolutions during its 24th meeting, including the approval of the 2025 semi-annual report and profit distribution plan, as well as the establishment of a new plasma collection station project [1][2][3]. Group 1: Financial Reports and Profit Distribution - The board approved the 2025 semi-annual report and its summary with a unanimous vote of 9 in favor [1]. - The profit distribution plan for the first half of 2025 was approved, with a total distribution amount of 296,605,716.90 yuan (including tax), with no stock dividends or capital reserve transfers [1][2]. Group 2: Fund Management and Risk Assessment - The board approved the special report on the storage and actual use of raised funds for the first half of 2025, with a unanimous vote of 9 in favor [2]. - A risk assessment report regarding China National Pharmaceutical Group Financial Co., Ltd. was approved, indicating no significant deficiencies in risk management and that the financial services provided were fair and reasonable [2][3]. Group 3: Corporate Governance and New Projects - The board approved the rules for the general manager's office meetings with a unanimous vote of 9 in favor [3]. - The board agreed to the investment in the construction of a new plasma collection station by Chengdu Rongsheng Pharmaceutical Co., Ltd., with the project receiving prior approval from the strategic and investment committee [3]. - The company agreed to donate 400,000 yuan to the Gansu Red Cross for emergency disaster relief and post-disaster reconstruction efforts [3].

Core Points - The company held its 24th meeting of the 5th Board of Directors on May 30, 2025, where several resolutions were passed regarding transactions with China Energy Conservation and Environmental Protection (Hong Kong) Treasury Management Co., Ltd [1][2][3] - The board approved a financial service agreement and related transactions, which will be submitted for shareholder approval at the upcoming extraordinary general meeting [1][2] - The board also approved a risk assessment report concerning the aforementioned company and an emergency risk disposal plan for financial cooperation [2][3] - The company has scheduled its first extraordinary general meeting of 2025 for June 16, 2025, at 15:00 [4] Summary by Categories Board Meeting Resolutions - The board meeting was attended by all 9 directors, and resolutions were passed with a voting result of 3 in favor and 6 abstentions regarding the financial service agreement [1][2] - The risk assessment report was also approved with the same voting results [2][3] - An emergency risk disposal plan was approved with identical voting results [3] Upcoming Shareholder Meeting - The company will hold its first extraordinary general meeting on June 16, 2025, with all 9 votes in favor of the meeting [4]

Core Points - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, and will amend its articles of association accordingly [1][2] - The company signed a financial services agreement with China Electronics Technology Finance Co., Ltd., which is deemed beneficial for the company's sustainable development and does not affect its independence [2] - A risk disposal plan related to financial operations with China Electronics Technology Finance Co., Ltd. was approved to safeguard the company's and shareholders' interests, particularly those of minority shareholders [2] - A risk assessment report on China Electronics Technology Finance Co., Ltd. was approved, confirming that the company's internal controls and operational management meet the requirements for providing financial services without harming the interests of the company or minority shareholders [2][3]